Nair Anugrah, Tuan Lukah Q, Jones-Lewis Natasha, Raja Deep Chandh, Shroff Jenish, Pathak Rajeev Kumar
Department of Cardiac Electrophysiology, Canberra Heart Rhythm Centre, Canberra, ACT 2605, Australia.
ANU College of Health and Medicine, Australian National University, Acton Campus, Canberra, ACT 0200, Australia.
J Cardiovasc Dev Dis. 2024 May 9;11(5):148. doi: 10.3390/jcdd11050148.
Heart failure (HF) presents a significant global health challenge recognised by frequent hospitalisation and high mortality rates. The assessment of left ventricular (LV) ejection fraction (EF) plays a crucial role in diagnosing and predicting outcomes in HF, leading to its classification into preserved (HFpEF), reduced (HFrEF), and mildly reduced (HFmrEF) EF. HFmrEF shares features of both HFrEF and HFpEF but also exhibits distinct characteristics. Despite advancements, managing HFmrEF remains challenging due to its diverse presentation. Large-scale studies are needed to identify the predictors of clinical outcomes and treatment responses. Utilising biomarkers for phenotyping holds the potential for discovering new treatment targets. Given the uncertainty surrounding optimal management, individualised approaches are imperative for HFmrEF patients. This chapter examines HFmrEF, discusses the rationale for its re-classification, and elucidates HFmrEF's key attributes. Furthermore, it provides a comprehensive review of current treatment strategies for HFmrEF patients.
心力衰竭(HF)是一项重大的全球健康挑战,其住院率高和死亡率高已得到公认。左心室(LV)射血分数(EF)的评估在HF的诊断和预后预测中起着关键作用,从而将其分为射血分数保留的心衰(HFpEF)、射血分数降低的心衰(HFrEF)和射血分数轻度降低的心衰(HFmrEF)。HFmrEF兼具HFrEF和HFpEF的特征,但也有其独特之处。尽管取得了进展,但由于HFmrEF表现多样,对其进行管理仍具有挑战性。需要开展大规模研究来确定临床结局和治疗反应的预测因素。利用生物标志物进行表型分析有可能发现新的治疗靶点。鉴于最佳管理存在不确定性,针对HFmrEF患者采取个体化方法势在必行。本章将探讨HFmrEF,讨论对其重新分类的理由,并阐明HFmrEF的关键属性。此外,还对HFmrEF患者当前的治疗策略进行了全面综述。